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A B S T R A C T
Background
Bronchiectasis is increasingly recognized as a major cause of respiratory morbidity especially in developing countries. Even in affluent
countries, bronchiectasis is increasingly seen in some community subsections (e.g. Aboriginal communities) and occurs as a comorbidity
and disease modifier in respiratory diseases such as chronic obstructive pulmonary disease (COPD). Respiratory exacerbations in people
with bronchiectasis are associated with reduced quality of life, accelerated pulmonary decline, hospitalisation and even death. Conjugate
pneumococcal vaccine is part of the routine infant immunisation schedule in many countries. Current recommendations for additional
pneumococcal vaccination include children and adults with chronic suppurative disease.
Objectives
To evaluate the effectiveness of pneumococcal vaccine as routine management in children and adults with bronchiectasis in (a) reducing
the severity and frequency of respiratory exacerbations and (b) pulmonary decline.
Search methods
TheCochrane Register of Controlled Trials (CENTRAL), theCochrane Airways Group Specialised Register,MEDLINE and EMBASE
databases were searched by the Cochrane Airways Group. Pharmaceutical manufacturers of pneumococcal vaccines were also contacted.
The latest searches were performed in November 2008.
Selection criteria
All randomised controlled trials that utilised pneumococcal vaccine on children and adultswith bronchiectasis. All types of pneumococcal
vaccines were included.
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. No eligible trials were identified and thus no data was
available for analysis. One small non-randomised controlled trial in children was reported.
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Main results
One randomised controlled open label study in 167 adults with chronic lung disease (bronchiectasis and other diseases associated with
bronchiectasis) compared 23-valent pneumococcal (PV) and influenza vaccine with influenza vaccine alone (control group). The study
found a significant reduction in acute infective respiratory exacerbations in the PV group compared to the control group, OR=0.48
(95%CI 0.26, 0.88); number needed to treat to benefit = 6 (95%CI 4, 32) over 2-years. There was however no difference in episodes
of pneumonia between groups and no data on pulmonary decline was available. In another study, a benefit in elimination of Strep.
pneumoniae in the sputum was found in a non-randomised trial in children but no clinical effect was described.
Authors’ conclusions
Current but limited evidence support the use of 23-valent pneumococcal vaccine as routine management in adults with bronchiectasis.
Circumstantial evidence also support the use of routine 23-valent pneumococcal vaccination in children with bronchiectasis. Further
randomised controlled trials examining the efficacy of this intervention using various vaccine types in different age groups are needed.
There is no data on the efficacy of pneumococcal vaccine on pulmonary decline. With the lack of evidence in how often the vaccine
should be given, it is recommended that health providers adhere to national guidelines.
P L A I N L A N G U A G E S U M M A R Y
Pneumonia (pneumococcal) vaccines for children and adults with bronchiectasis
In many countries pneumonia vaccination (for the protection against infection of the bacteria pneumococcus), is part of the immunisa-
tion schedule for infants as well as for people with bronchiectasis. In this review, our search for randomised control trials that examined
the effectiveness of pneumococcal vaccines for people with bronchiectasis revealed one randomised and one quasi-controlled trial. We
conclude that, albeit the limitations of the review, adults and children (when age appropriate) with bronchiectasis should be vaccinated
with the 23-valent polysaccharide pneumococcal vaccine as suggested in many national guidelines. Due to absence of data on how
often the vaccine should be given, we recommend that national guidelines be followed until further evidence is available.
B A C K G R O U N D
Bronchiectasis, sometimes termed an ’orphan’s disease’ (Callahan
2002) is increasingly recognized as a major cause of respiratory
morbidity especially in developing countries (Karadag 2005) and
in pockets of affluent countries (Chang 2003, Singleton 2000).
Of diverse aetiology, bronchiectasis is often a result of repeated
respiratory infections or may be due to rare immune deficiencies.
Increasingly recognised as a common final pathway for a variety
of diseases, it is seen to complicate both common and uncom-
mon respiratory illnesses such as COPD, bronchiolitis obliterans,
pan bronchiolitis (Poletti 2006), pneumoconiosis (Altin 2004),
interstitial lung disease and sarcoidosis (Patel 2004, Chang 1998,
Lewis 2002) and also secondary pulmonary illnesses such as au-
toimmune diseases and post tuberculosis (TB) (Buckles 1951). Its
coexistence increases the morbidity and mortality of the under-
lying disease (Patel 2004, Lewis 2002, Keistinen 1997). For in-
stance, bronchiectasis is reported to occur in 29-50% of COPD
(Patel 2004, O’Brien 2000) and when present, increases the sever-
ity and frequency of respiratory exacerbations (Patel 2004, Gursel
2006). Thus, management of the symptoms and prevention of
progression of bronchiectasis is important.
The dominant symptoms and signs of bronchiectasis are a pro-
ductive or wet cough, dyspnoea on exertion and presence of other
respiratory signs (clubbing, chest wall deformity, respiratory noises
such as wheeze or crepitations on auscultation). In the long term,
pulmonary declinemay occur (Keistinen 1997, Twiss 2006). Chil-
dren and adults with bronchiectasis suffer from recurrent acute
exacerbations, some necessitating inpatient care. Effective man-
agement regimes for bronchiectasis should improve quality of life,
reduce the frequency and severity of respiratory exacerbations and
rate of pulmonary decline. Cole’s ’vicious circle hypothesis’ sug-
gestsmicrobial colonizationor infection as a key factor in its patho-
physiology as this often leads to bronchial obstruction and a nor-
mal or exaggerated inflammatory response (Cole 1986). Treatment
modalities that prevent or limit respiratory infections should thus,
prevent or reduce respiratory decline. Respiratory infection alone
increases morbidity and reduces the quality of life in those with
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bronchiectasis (Martinez-Garcia 2005). Pneumococcal respiratory
infections is a common respiratory pathogen in acute (Lucero
2004) and chronic respiratory diseases (Devitt 1977). Prevention
of pneumococcal infections through the use of pneumococcal vac-
cine should in turn, be a useful routine management modality for
children and adults with bronchiectasis. Indeed 5-yearly pneumo-
coccal vaccination is recommended for patients with bronchiecta-
sis (Chang 2002).
Pneumococcal vaccines are available in two major types; the older
pneumococcal polysaccharide vaccine and the more recent pneu-
mococcal conjugate vaccine. The 23-valent polysaccharide vac-
cine (PPV23) contains polysaccharide antigen from 23 serotypes
and vaccine efficacy against invasive disease is estimated at 38-
53% (Conaty 2004). Although clinical trials in younger adults
have generally shown efficacy against pneumococcal pneumonia
and, or bacteraemia, the trial evidence in the elderly is less robust
(Honkanen 1999). Effectiveness in case-control studies generally
range from 56-81% except Forrester et al who demonstrated no
effectiveness (Forrester 1987). The PPV23 vaccine is relatively in-
effective in young children aged under 2 years (Lee 2003). The
heptavalent pneumococcal conjugated vaccine (PCV7) is directed
against seven serotypes and recommended for use in children less
than 5 years of age (McEllistrem 2005). Universal childhood vac-
cination in the United States has resulted in 70% decrease in in-
vasive pneumococcal disease (IPD) in children <2 years and indi-
rectly, contributed to prevention of adult IPD (Lexau 2005). The
possibility of replacement serotype disease mandates continued
data surveillance (McEllistrem 2005). Vaccines also incur cost and
can result in adverse reactions, mostly occurring as local pain and
swelling (Walker 2005, Jackson 2006). A review on the efficacy of
pneumococcal vaccines for bronchiectasis will help guide clinical
practice.
Efficacy of pneumococcal vaccines for other chronic respira-
tory diseases (Sheikh 2002, Granger 2006) and otitis media
(Straetemans 2004) are covered in other Cochrane reviews. This
systematic review will evaluate the evidence of efficacy of pneu-
mococcal vaccination in children and adults with bronchiectasis.
O B J E C T I V E S
To evaluate the effectiveness of pneumococcal vaccine as routine
management in children and adults with bronchiectasis in (a) re-
ducing the severity and frequency of respiratory exacerbations and
(b) pulmonary decline.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials using pneumococcal vaccine in
patients with bronchiectasis.
Types of participants
Adults or children with bronchiectasis (defined clinically or radi-
ologically).
Exclusion criteria: Participants with other diseases where
bronchiectasis is not present.
Types of interventions
All randomised controlled trials that utilised pneumococcal vac-
cine on children and adults with bronchiectasis. All types of pneu-
mococcal vaccines were included.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures:
(A) for short term effectiveness (12 months or less)
a) proportions of participants who had respiratory exacerbations
b) proportions of participants who were hospitalised,
c) total numbers of days with respiratory symptoms
d) total number of hospitalised days
e) mean difference in bronchiectasis severity control (QOL, cough
diary, Likert scale, visual analogue scale, level of interference of
cough, cough diary, etc),
f ) proportions experiencing adverse effects of the intervention,
(e.g. local reaction, exacerbation immediately post vaccination,
systemic effects (myalgia, fever, fatigue), etc)
Outcomes (a) to (e) will be examined globally as well as also specif-
ically to proven pneumococcal infections (from airway specimens
or rising titres)
(B) for medium to long term outcomes (more than 1 year)
g) radiology scores (high resolution computed tomography scans
or chest radiograph)
h) lung function
I) bronchiectasis severity control (QOL, cough diary, Likert scale,
visual analogue scale, level of interference of cough, cough diary,
etc),
j) relevant airway markers of inflammation.
k) other non-respiratory outcomes (otitis media, bacteraemia,
meningitis, etc) caused by pneumococcus.
Search methods for identification of studies
The following topic search strategy was used to identify relevant
randomised controlled trials from electronic databases:
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(“bronchiectasis” OR “suppurative lung disease”) AND ((vaccin*
OR immunis*) AND (pneum*)) (all as textword or index terms).
For the full strategies see Appendix 1.
Trials were identified from the following sources:
1. The Cochrane Airways Group Specialised Trials Register
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL)
3. MEDLINE (1966 to Nov 2008). Topic search strategy com-
bined with the RCT search filter as outlined in the Airways Group
module.
4. OLDMEDLINE (1950 to 1965). Topic search strategy com-
bined with the RCT search filter as outlined in the Airways Group
module.
5. EMBASE (1980 to Nov 2008).Topic search strategy combined
with the RCT search filter as outlined in the Airways Group mod-
ule.
6. The list of references in relevant publications.
7. Written communication with the authors of trials would have
been included in the review if necessary.
7. Pharmaceutical companies that manufacture pneumococcal
vaccines.
Data collection and analysis
Retrieval of studies: From the title, abstract, or descriptors, two
reviewers (CC, AC) independently reviewed literature searches to
identify potentially relevant trials for full review. Searches of bibli-
ographies and texts were conducted to identify additional studies.
From the full text using specific criteria, the same two reviewers
independently selected trials for inclusion. Agreement would have
been measured using kappa statistics. Disagreement would have
been resolved by adjudication (RS and PM).
It was planned that trials that satisfied the inclusion criteria would
have been reviewed and the following information recorded: study
setting, year of study, source of funding, patient recruitment de-
tails (including number of eligible subjects), inclusion and exclu-
sion criteria, other symptoms, randomisation and allocation con-
cealment method, numbers of participants randomised, blinding
(masking) of participants, care providers and outcome assessors,
dose and type of intervention, duration of therapy, co-interven-
tions, numbers of patients not followedup, reasons forwithdrawals
from study protocol (clinical, side-effects, refusal and other), de-
tails on side-effects of therapy, andwhether intention-to-treat anal-
yses were possible. Data would have been extracted on the out-
comes described previously. Further information would have been
requested from the authors when required.
The Revman 5 ’risk of bias tool’ as outlined in the Cochrane
handbook (Higgins 2008) was utilised.
STATISTICS
Results from studies that met the inclusion criteria and reported
any of the outcomes of interest were included in themeta-analyses
when possible. For continuous variables, the summary weighted
odds ratio and95%confidence interval (fixed effectsmodel)would
have been calculated (Cochrane statistical package, RevMan ver-
sion 5). Studies using cross-over designs would be of limited value
and it was planned that only the first arm of the cross-study (if any)
would be utilised. Numbers needed to treat for benefit (NNTB)
was calculated from the pooled OR and its 95% CI applied to
a specified baseline risk using an online calculator (Cates 2003).
If studies reported outcomes using different measurement scales,
the standardised mean difference would have been estimated. Any
heterogeneity between the study results would have been described
and tested to see if it reached statistical significance using a chi-
squared test. The 95% confidence interval estimated using a ran-
dom effects model would have been included whenever there are
concerns about statistical heterogeneity.
SUB-GROUP ANALYSIS:
The following a priori sub-group analyses was planned:
1. children (aged 18 years or less) and adults (>18 years)
2. types of pneumococcal vaccine
3. type of control group
4. participant type (bronchiectasis as primary disease vs bronchiec-
tasis as co-existent disease)
5. severity of bronchiectasis (based on lung function)
Sensitivity analyses were also planned to assess the impact of the
potentially important factors on the overall outcomes:
a) study quality;
b) variation in the inclusion criteria;
c) differences in the medications used in the intervention and
comparison groups;
d) differences in outcome measures;
e) analysis using random effects model;
f ) analysis by “treatment received”; and
g) analysis by “intention-to-treat”.
R E S U L T S
Description of studies
In the original search (2006) the Airways Group specialised regis-
ter/search identified 44 potentially relevant titles. After assessing
the abstracts, 3 publications were considered for inclusion into
review including one non-English article (Russian). Of the 3 po-
tentially relevant publication but none fulfilled the study eligibil-
ity criteria (see Table of excluded studies). No additional studies
were found in the review articles. No additional data were available
from the two pharmaceutical companies contacted (Merck Sharp
& Dohme and Wyeth in Australia). The 2007 search revealed 5
abstracts of which none fulfilled the inclusion criteria. The 2008
search revealed 8 papers and one study (Furumoto 2008) was in-
cluded.
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The included study has been described in the Characteristics of
included studies table. Some subjects had very severe lung dis-
ease (59 on home oxygen, 11 on home ventilation). The study
was included as some subjects were clearly described as having
bronchiectasis. The respiratory condition the other subjects had,
has a large overlap with bronchiectasis especially when the disease
is severe. Subjects were followed up for 2 years. There were no ran-
domised controlled studies in children that assessed clinical out-
comes. There was one quasi controlled study (Ryzhov 2005) that
utilised a comparative group published in Russian (Ryzhov 2005).
In this study (Ryzhov 2005) in children with chronic lung disease
(including bronchiectasis), 25 were vaccinated with PPV23, 13
with Haemophilus influenzae vaccine and 40 children were not
vaccinated. As there was otherwise little data, this study could not
be included in the meta-analysis.
Risk of bias in included studies
Please see risk of bias table in included studies section. The sole
randomised study (Furumoto 2008) included in this review has
high risk of performance and detection bias.
Effects of interventions
Adults
Effect on exacerbations (Analysis 1.1):
For number of people having had any respiratory exacerbations,
the PV23 group was significantly better (less subjects with exac-
erbations) then the control group, OR 0.53 (95%CI 0.29, 0.99)
Figure 1, NNTB over 2-years was 7 (95%CI 4, 424). With fur-
ther evaluation, the difference between groups was mainly re-
lated to infective exacerbations (i.e. respiratory symptoms with
increase in blood white cell count or serum C-reactive protein, as
described in Characteristics of included studies). Comparing the
PV23 group to controls, the OR for infective exacerbations was
OR=0.48 (95%CI 0.26, 0.88); number needed to treat to benefit=
6 (95%CI 4, 32) over 2-years, see Figure 2. That for non-infective
exacerbations was non significant, OR 1.42 (0.48, 4.19).
Figure 1. Forest plot of comparison: 1 Adults, outcome: 1.2 Number of people with acute respiratory
exacerbation.
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Figure 2. Cates plot for NNT (B) over 2-years in reduction of infective exacerbation comparing PV23
vaccination to control in adults with chronic lung disease
Effect on pneumonia (Analysis 1.2): There was no difference be-
tween groups for the outcome of pneumonia
Other outcomes: Furumoto 2008 did not report on any pul-
monary function. Seven subjects in each group (8.4% of the co-
hort studied) died during the follow up period of the study.
Children
There was only one study in children with bronchiectasis and this
study utilised a comparative group, (i.e. a non-randomised study)
published in Russian (Ryzhov 2005). In this study (Ryzhov 2005)
in children with chronic lung disease (including bronchiectasis),
25 were vaccinated with PPV23, 13 with Haemophilus influen-
zae vaccine and 40 children were not vaccinated. The authors de-
scribed that, a year after vaccination with PPV23, S. pneumoniae
were isolated in monoculture in 3 out of 25 cases (88% elimina-
tion) (Ryzhov 2005).
It was not possible to perform any relevant sub-analysis.
D I S C U S S I O N
In this review that evaluated the efficacy of pneumococcal vaccine
in people with bronchiectasis for pulmonary outcomes, we found
only one randomised controlled trial that was subject to bias as
it was an open-labelled trial. Nevertheless the study in 167 adults
with chronic lung disease found that PV23 vaccination signifi-
cantly reduced the number of people with respiratory exacerba-
tion with NNTB of 7 (95%CI 4, 424) over 2-years. The majority
of this effect related to infective exacerbations, NNTB 6 (95%CI
4, 32) over 2-years. There was no difference between groups on
number with pneumonia and no data for pulmonary decline was
found. One controlled study that was not randomised (Ryzhov
2005) described efficacy with respect to microbiology of the spu-
tum (88% elimination of S pneumoniae) but clinical evaluation
was not examined in children.
Large trials andmeta-analysis have demonstrated that pneumococ-
cal vaccination protects children and adults from invasive pneu-
mococcal disease (de Roux 2005), thus many recommendations
exist for regular pneumococcal vaccination for those at risk (in-
cluding patients with suppurative lung disease). This Cochrane
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review has significant limitations with the lack of studies. . Whilst
we cannot always “wait for perfect data”, others have cautioned
against “availability creep” with respect to the gap between policy
and evidence (Jefferson 2006). Until additional RCTs are under-
taken to examine the question, we cannot be absolutely confident
with the findings of this review that routine pneumococcal vac-
cination in children and adults with bronchiectasis is beneficial.
The feasibility of performing RCTs in this target group is in ques-
tion. For now, as children and adults with bronchiectasis are at
increased risk for pneumonia and pneumococcal disease and there
is some evidence that pneumococcal vaccine can reduce pneumo-
nia and invasive pneumococcal disease (Lucero 2004), it would be
prudent that providers follow guidelines from the national bodies
such as Advisory Committee on Immunization Practices (in USA)
(ACIP) and NIPS (Australia) (NIPS) regarding recommendations
for pneumococcal vaccination of persons with bronchiectasis.
It is debatable whether the study (Furumoto 2008) we have in-
cluded in this review fulfilled all the inclusion criteria, specifically
that related to the diagnosis. We decided to include the study be-
cause a subgroup definitely had bronchiectasis and all the lung
conditions in the subjects have a large overlap with bronchiectasis
especially when the disease is severe. Although the study did not
describe the severity of the chronic lung disease in all the subjects,
it is likely that they were in the severe spectrum (35.3% of cohort
was on ambulatory oxygen and 6.6% was on home ventilation).
Unless a HRCT scan is performed on each subject, it is very dif-
ficult to ascertain whether radiological bronchiectasis is present.
The study was also limited with a risk of performance and detec-
tion bias. Nevertheless, in infective exacerbations where the great-
est significance between groups was found, objective blood tests
were utilised.
There was no data on how frequent pneumococcal vaccine should
be given after the initial vaccination. Some advocate repeating
PV23 after 5 years. In the absence of data on frequency of vacci-
nation, we advocate that national guidelines be adhered to.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Limited evidence support the routine use of polysaccharide 23-va-
lent pneumococcal vaccine in adults with chronic lung disease in-
cluding those with bronchiectasis. Other circumstantial data also
suggests that pneumococcal vaccination is beneficial in children.
There is no data on the efficacy of pneumococcal vaccine on pul-
monary decline. There is also no data on how often the vaccina-
tion should be repeated. With the lack of evidence on this, it is
recommended that health providers adhere to national guidelines.
Individual risk factors for adverse events should be taken into ac-
count.
Implications for research
Randomised controlled trials to establish the efficacy of pneumo-
coccal vaccination in reducing severity and frequency of respiratory
exacerbations and pulmonary decline in people with bronchiecta-
sis are needed. As vaccine response alters with age, age-based co-
horts should include young children (less than 2 years), children,
adults and older adults. Various vaccine types and microbiologi-
cal surveillance for possible serotype replacement should also be
examined in these RCTs. However the difficulty in performing a
RCT in the target group is acknowledged.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Furumoto 2008
Methods Multicentre parallel RCT involving 13 hospitals in the district of Kyushu and Okinawa
(Japan) between November 2001 and April 2002. Subjects were seen monthly and with
exacerbations, they visited a study physician
Participants 191 enrolled but 167 completed. All had chronic lungdisease (COPD(n=55), bronchiec-
tasis (20), sequelae of pulmonary tuberculosis (50), sarcoidosis (1), interstitial lung dis-
ease (9), diffuse pan bronchiolitis (5), pneumoconiosis (14), bronchial asthma (13))
Inclusion criteria were patients with chronic lung disease who previously experienced
acute exacerbations, were able to comply with a schedule of monthly clinical visits and
were between40 and80years of age. Exclusion criteria: Patientswhowere pregnant or had
immunocompromised conditions (e.g. active malignant diseases, renal insufficiency in
dialysis or HIV infection, hypogammaglobulinaemia, anatomical or functional asplenia
and who had previously received 23-valent PV
Mean age: pneumococcal vaccine (PV) with influenza vaccine (IV) group=67.8, SD 9.
5 years; IV alone group=70.1 SD 7.4 years
Gender: PV group=60 (69%), IV group=46 (57.5%)
Home O2 use: PV group=27 (31%), IV group=32 (40%)
Home non-invasive pressure ventilation: PV group=6 (6.9%), IV group=5 (6.3%)
Interventions 23-valent pneumococcal vaccine (PV) and influenza vaccine (IV) compared to influenza
vaccine alone. PV + IV group were separately immunized with 0.5 ml of PV and 0.5 ml
of IV on separate occasions in 1month intervals, the participants in the IV group were
immunized with 0.5 ml of IV alone
Outcomes Pneumonia defined as either clinical symptoms (cough, sputum or fever) plus increased
white blood cell counts or serum C-reactive protein, and the appearance of a new infil-
tration on a chest radiograph
Acute respiratory exacerbation defined by presence of criteria: (1) increased dyspnoea,
(2) increased sputum volume and (3) increased sputum purulence, and (4) absence of
newly appeared infiltration on a chest radiograph. Acute exacerbation was diagnosed
when two of the three respiratory symptoms existed or when one of these and one of
additional symptoms, such as a fever without any other causes or increased cough was
present
Acute infective respiratory exacerbation: above plus when the laboratory examinations
revealed an increase in white blood cell counts (WCC) or serum C-reactive protein
(CRP), in addition to the clinical symptoms of acute exacerbation
Acute non-infective respiratory exacerbation: clinical symptoms of acute exacerbation
without increase in WCC or serum CRP
Follow-up period was 2-years.
Notes As all diseases in the inclusion list develop bronchiectasis, paper included
Risk of bias
Bias Authors’ judgement Support for judgement
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Furumoto 2008 (Continued)
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Low risk Use of envelopes
Blinding (performance bias and detection
bias)
Pneumonia
High risk Open label trial
Blinding (performance bias and detection
bias)
Acute infective respiratory exacerbation
High risk Open label trial
Blinding (performance bias and detection
bias)
Acute non-infective respiratory exacerba-
tion
Low risk Defined by objective blood results; thus
presumed blinded outcome
Incomplete outcome data (attrition bias)
Pneumonia
Low risk Proportion of possible missing outcomes
highly unlikely to have clinical relevant im-
pact on intervention effect estimate (low
numbers of drop outs and outcomes in
both groups 0.096 episodes per person
year)
Incomplete outcome data (attrition bias)
Acute infective respiratory exacerbation
Unclear risk Numbers lost and withdrawn in both
groups given (7 in active arm, 17 in control
arm)
Incomplete outcome data (attrition bias)
Acute non-infective respiratory exacerba-
tion
Unclear risk Numbers lost and withdrawn in both
groups given (7 in active arm, 17 in control
arm)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ryzhov 2005 Non RCT. This study in Russian was a comparative study in 40 controls (unvaccinated ) and 25 children with
chronic lung disease (including bronchiectasis) using Pneumovax 23. Hib vaccination was examined in another
group
van Kessel 2005 Non RCT. Study examined antibody response to polysaccharide pneumococcal vaccine in 26 patients with
bronchiectasis of unknown aetiology
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(Continued)
Vendrell 2005 Non RCT. Study examined antibody response to a pneumococcal unconjugate vaccine and an Haemophilus
influenzae type b conjugate vaccine in all consecutive adult patients with bronchiectasis of unknown etiology
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D A T A A N D A N A L Y S E S
Comparison 1. Adults
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of people with one
or more acute respiratory
exacerbation
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Any exacerbation 1 167 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.29, 0.99]
1.2 Infective exacerbations 1 167 Odds Ratio (M-H, Fixed, 95% CI) 0.48 [0.26, 0.88]
1.3 Non-infective
exacerbations
1 167 Odds Ratio (M-H, Fixed, 95% CI) 1.42 [0.48, 4.19]
2 Number of subjects with
pneumonia
1 167 Odds Ratio (M-H, Fixed, 95% CI) 1.00 [0.43, 2.33]
WH A T ’ S N E W
Last assessed as up-to-date: 4 December 2008.
Date Event Description
5 June 2014 Amended PLS title amended
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 2, 2007
Date Event Description
12 March 2009 Amended Contact details changed
4 December 2008 New citation required and conclusions have changed Study on 167 people added to review
12 November 2008 New search has been performed Literature search re-run
16 April 2008 Amended Converted to new review format.
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(Continued)
10 December 2006 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
For the protocol: Protocol was written by both CC and AC. RS reviewed the protocol. For the review: CC and AC selected articles
from search, extracted data and wrote the review. RS and PM contributed to writing the review and would have been adjudicators if
disagreements had occurred.
D E C L A R A T I O N S O F I N T E R E S T
None declared.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
External sources
• National Health and Medical Research Council, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Bronchiectasis [∗complications]; Pneumococcal Infections [∗prevention & control]; Pneumococcal Vaccines [∗therapeutic use]; Respi-
ration Disorders [∗prevention & control]
MeSH check words
Adult; Child; Humans
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